Consequences of topoisomerase II inhibition in early embryogenesis of Drosophila revealed by in vivo confocal laser scanning microscopy.
The regulation of DNA topology by topoisomerase II from Drosophila melanogaster has been studied extensively by biochemical methods but little is known about its roles in vivo. We have performed experiments on the inhibition of topoisomerase II in living Drosophila blastoderm embryos. We show that the enzymatic activity can be specifically disrupted by microinjection of antitopoisomerase II antibodies as well as the epipodophyllotoxin VM26, a known inhibitor of topoisomerase II in vitro. By labeling the chromatin of live embryos with tetramethylrhodamine-coupled histones, the effects of inhibition on nuclear morphology and behaviour was followed in vivo using confocal laser scanning microscopy. Both the antibodies and the drug prevented or hindered the segregation of chromatin daughter sets at the anaphase stage of mitosis. In addition, high concentrations of inhibitor interfered with the condensation of chromatin and its proper arrangement into the metaphase plate. The observed effects yielded non-functional nuclei, which were drawn into the inner yolk mass of the embryo. Concurrently, undamaged nuclei surrounding the affected region underwent compensatory division, leading to the restoration of the nuclear population, and thereby demonstrating the regulative capacity of Drosophila blastoderm embryos.
Abteilung Molekulare Biologie, Max Planck Institut für biophysikalische Chemie, Göttingen, FRG.
P
P
Buchenau
H
H
Saumweber
D J
DJ
Arndt-Jovin
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000911:Antibodies, Monoclonal; D002455:Cell Division / Q000502:physiology; D002467:Cell Nucleus / Q000502:physiology; D002843:Chromatin / Q000502:physiology; D004250:DNA Topoisomerases, Type II / Q000276:immunology / Q000502:physiology*; D004331:Drosophila melanogaster / Q000196:embryology / Q000201:enzymology*; D007834:Lasers; D008853:Microscopy / Q000379:methods; D008938:Mitosis / Q000502:physiology; D013713:Teniposide / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors
D000906:Antibodies; D000911:Antibodies, Monoclonal; D002843:Chromatin; D059005:Topoisomerase II Inhibitors; D013713:Teniposide; D004250:DNA Topoisomerases, Type II